Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 SKYBRIDGE study evaluating Peluntamig (PT217) in DLL3-expressing neuroendocrine carcinomas; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma
• Gastroenteropancreatic Neuroendocrine Carcinoma
• Large Cell Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma
• Neuroendocrine Prostate Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Peluntamig (PT217)

Snippet

Sponsor: Phanes Therapeutics | Conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1, Phase 2 | Status: RECRUITING